Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794152 | 0.81 | ELANE (0.53) | KDM4EDDB1CRBNGPR3HTR2A | |
| SCHEMBL1777889 | 0.81 | ELANE (0.53) | KDM4EDDB1CRBNGPR3HTR2A | |
| SCHEMBL22186619 | 0.77 | HTR4 (0.41) | ALDH1A1 | |
| SCHEMBL19986782 | 0.74 | GPR3 (0.44) | KDM4EDDB1CRBNGPR3HTR2A | |
| SCHEMBL29901540 | 0.74 | GPR3 (0.44) | KDM4EDDB1CRBNGPR3HTR2A | |
| SCHEMBL15643691 | 0.72 | GLS (0.39) | KDM4EGPR3ELANECNR1CNR2 | |
| SCHEMBL496589 | 0.72 | KDM4E (0.62) | KDM4EELANEALDH1A1CYP3A4TSHR | |
| SCHEMBL30251861 | 0.72 | KDM4E (0.62) | KDM4EELANEALDH1A1CYP3A4TSHR | |
| SCHEMBL30506312 | 0.71 | GLS (0.56) | KDM4EDDB1CRBNGPR3HTR2A | |
| SCHEMBL147947 | 0.71 | GLS (0.56) | KDM4EDDB1CRBNGPR3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | claimed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | claimed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | claimed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | claimed |
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | claimed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | claimed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | claimed |
| WO-2024145662-A1 | 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS | ALTAY THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | HOLOSMEDIC (KR) | 2024-03-28 | — | — | US | disclosed |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004002999-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002422-A2 | 2’-C-METHYL-3’-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | KDM4E 3122/4885DDB1 3873/4885CRBN 1418/4885 |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | SLC11A2, ABCC1, TSG101 | KDM4E 3814/4885DDB1 611/4885CRBN 2338/4885 |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | KDM4E 4142/4885DDB1 1061/4885CRBN 3707/4885 |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | NSUN2, BCDIN3D, METTL16 | KDM4E 148/4885DDB1 2902/4885CRBN 1253/4885 |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | VIP, PNKP, PEPD | KDM4E 4142/4885DDB1 1061/4885CRBN 3707/4885 |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | KDM4E 1216/4885DDB1 2319/4885CRBN 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.